Skip to main
SUPN
SUPN logo

Supernus Pharmaceuticals (SUPN) Stock Forecast & Price Target

Supernus Pharmaceuticals (SUPN) Analyst Ratings

Based on 2 analyst ratings
Buy
Strong Buy 0%
Buy 100%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Supernus Pharmaceuticals Inc. is gaining attention for its innovative product, ONAPGO, aimed at treating advanced Parkinson's disease, which suggests a growing interest and potential market traction in its pipeline. The company has a history of conservative management, indicating that they might increase peak sales estimates as they understand demand dynamics better. The positive sentiment surrounding ONAPGO, coupled with the broader neuroscience portfolio that addresses critical neurological and psychiatric conditions, supports a favorable outlook for Supernus Pharmaceuticals.

Bears say

Supernus Pharmaceuticals Inc faces significant commercial execution risks, which could hinder its market potential and negatively impact revenue growth. Additionally, the inherent risks associated with clinical trials could lead to unfavorable outcomes, including the possible rejection of regulatory approvals due to insufficient evidence of drug efficacy and safety. These factors collectively contribute to a concerning outlook for the company's future financial performance and ability to expand its product portfolio.

Supernus Pharmaceuticals (SUPN) has been analyzed by 2 analysts, with a consensus rating of Buy. 0% of analysts recommend a Strong Buy, 100% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Supernus Pharmaceuticals and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Supernus Pharmaceuticals (SUPN) Forecast

Analysts have given Supernus Pharmaceuticals (SUPN) a Buy based on their latest research and market trends.

According to 2 analysts, Supernus Pharmaceuticals (SUPN) has a Buy consensus rating as of Oct 15, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $64, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $64, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Supernus Pharmaceuticals (SUPN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.